MED18 and gastric cancer: Accordingly, it was proposed that SNHG3 also had a significant impact on the positive progression of GC in the study that displayed that MED18, a tumor suppressor in respect to proliferation, migration, and invasion of GC, was downregulated by SNHG3 epigenetically via methylating MED18 promoter by binding to EZH2 [95].